Semi-quantitative mass spectrometry in AML cells identifies new non-genomic targets of the EZH2 methyltransferase

Yordan Sbirkov, Colin Kwok, Amandeep Bhamra, Andrew J. Thompson, Veronica Gil, Arthur Z Zelent, Kevin Petrie

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function and loss-of-function, have been linked to a variety of haematological malignancies and solid tumours, suggesting a complex, context-dependent role of this methyltransferase. The successful implementation of molecularly targeted therapies against EZH2 requires a greater understanding of the potential mechanisms by which EZH2 contributes to cancer. One aspect of this effort is the mapping of EZH2 partner proteins and cellular targets. To this end we performed affinity-purification mass spectrometry in the FAB-M2 HL-60 acute myeloid leukaemia (AML) cell line before and after all-trans retinoic acid-induced differentiation. These studies identified new EZH2 interaction partners and potential non-histone substrates for EZH2-mediated methylation. Our results suggest that EZH2 is involved in the regulation of translation through interactions with a number of RNA binding proteins and by methylating key components of protein synthesis such as eEF1A1. Given that deregulated mRNA translation is a frequent feature of cancer and that eEF1A1 is highly expressed in many human tumours, these findings present new possibilities for the therapeutic targeting of EZH2 in AML.

Original languageEnglish (US)
Article number1440
JournalInternational Journal of Molecular Sciences
Volume18
Issue number7
DOIs
StatePublished - Jul 5 2017

Fingerprint

leukemias
Methyltransferases
Myeloid Cells
Acute Myeloid Leukemia
Mass spectrometry
Tumors
Mass Spectrometry
mass spectroscopy
tumors
cancer
protein synthesis
proteins
Proteins
Gene encoding
methylation
Methylation
RNA-Binding Proteins
FORTRAN
Tretinoin
cells

Keywords

  • Acute myeloid leukaemia
  • EEF1A1
  • EZH2
  • Mass spectrometry
  • Methylation

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Semi-quantitative mass spectrometry in AML cells identifies new non-genomic targets of the EZH2 methyltransferase. / Sbirkov, Yordan; Kwok, Colin; Bhamra, Amandeep; Thompson, Andrew J.; Gil, Veronica; Zelent, Arthur Z; Petrie, Kevin.

In: International Journal of Molecular Sciences, Vol. 18, No. 7, 1440, 05.07.2017.

Research output: Contribution to journalArticle

Sbirkov, Yordan ; Kwok, Colin ; Bhamra, Amandeep ; Thompson, Andrew J. ; Gil, Veronica ; Zelent, Arthur Z ; Petrie, Kevin. / Semi-quantitative mass spectrometry in AML cells identifies new non-genomic targets of the EZH2 methyltransferase. In: International Journal of Molecular Sciences. 2017 ; Vol. 18, No. 7.
@article{09c427eeec0846819bc5291be9d7e417,
title = "Semi-quantitative mass spectrometry in AML cells identifies new non-genomic targets of the EZH2 methyltransferase",
abstract = "Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function and loss-of-function, have been linked to a variety of haematological malignancies and solid tumours, suggesting a complex, context-dependent role of this methyltransferase. The successful implementation of molecularly targeted therapies against EZH2 requires a greater understanding of the potential mechanisms by which EZH2 contributes to cancer. One aspect of this effort is the mapping of EZH2 partner proteins and cellular targets. To this end we performed affinity-purification mass spectrometry in the FAB-M2 HL-60 acute myeloid leukaemia (AML) cell line before and after all-trans retinoic acid-induced differentiation. These studies identified new EZH2 interaction partners and potential non-histone substrates for EZH2-mediated methylation. Our results suggest that EZH2 is involved in the regulation of translation through interactions with a number of RNA binding proteins and by methylating key components of protein synthesis such as eEF1A1. Given that deregulated mRNA translation is a frequent feature of cancer and that eEF1A1 is highly expressed in many human tumours, these findings present new possibilities for the therapeutic targeting of EZH2 in AML.",
keywords = "Acute myeloid leukaemia, EEF1A1, EZH2, Mass spectrometry, Methylation",
author = "Yordan Sbirkov and Colin Kwok and Amandeep Bhamra and Thompson, {Andrew J.} and Veronica Gil and Zelent, {Arthur Z} and Kevin Petrie",
year = "2017",
month = "7",
day = "5",
doi = "10.3390/ijms18071440",
language = "English (US)",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

TY - JOUR

T1 - Semi-quantitative mass spectrometry in AML cells identifies new non-genomic targets of the EZH2 methyltransferase

AU - Sbirkov, Yordan

AU - Kwok, Colin

AU - Bhamra, Amandeep

AU - Thompson, Andrew J.

AU - Gil, Veronica

AU - Zelent, Arthur Z

AU - Petrie, Kevin

PY - 2017/7/5

Y1 - 2017/7/5

N2 - Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function and loss-of-function, have been linked to a variety of haematological malignancies and solid tumours, suggesting a complex, context-dependent role of this methyltransferase. The successful implementation of molecularly targeted therapies against EZH2 requires a greater understanding of the potential mechanisms by which EZH2 contributes to cancer. One aspect of this effort is the mapping of EZH2 partner proteins and cellular targets. To this end we performed affinity-purification mass spectrometry in the FAB-M2 HL-60 acute myeloid leukaemia (AML) cell line before and after all-trans retinoic acid-induced differentiation. These studies identified new EZH2 interaction partners and potential non-histone substrates for EZH2-mediated methylation. Our results suggest that EZH2 is involved in the regulation of translation through interactions with a number of RNA binding proteins and by methylating key components of protein synthesis such as eEF1A1. Given that deregulated mRNA translation is a frequent feature of cancer and that eEF1A1 is highly expressed in many human tumours, these findings present new possibilities for the therapeutic targeting of EZH2 in AML.

AB - Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function and loss-of-function, have been linked to a variety of haematological malignancies and solid tumours, suggesting a complex, context-dependent role of this methyltransferase. The successful implementation of molecularly targeted therapies against EZH2 requires a greater understanding of the potential mechanisms by which EZH2 contributes to cancer. One aspect of this effort is the mapping of EZH2 partner proteins and cellular targets. To this end we performed affinity-purification mass spectrometry in the FAB-M2 HL-60 acute myeloid leukaemia (AML) cell line before and after all-trans retinoic acid-induced differentiation. These studies identified new EZH2 interaction partners and potential non-histone substrates for EZH2-mediated methylation. Our results suggest that EZH2 is involved in the regulation of translation through interactions with a number of RNA binding proteins and by methylating key components of protein synthesis such as eEF1A1. Given that deregulated mRNA translation is a frequent feature of cancer and that eEF1A1 is highly expressed in many human tumours, these findings present new possibilities for the therapeutic targeting of EZH2 in AML.

KW - Acute myeloid leukaemia

KW - EEF1A1

KW - EZH2

KW - Mass spectrometry

KW - Methylation

UR - http://www.scopus.com/inward/record.url?scp=85022075761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022075761&partnerID=8YFLogxK

U2 - 10.3390/ijms18071440

DO - 10.3390/ijms18071440

M3 - Article

C2 - 28678185

AN - SCOPUS:85022075761

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 7

M1 - 1440

ER -